Press Release

Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the American Society of Nephrology (ASN) Kidney Week 2022

October 14, 2022 at 8:00 AM EDT
  • Updated interim data to be presented from the IgA nephropathy (IgAN) patient cohort of the atrasentan phase 2 AFFINITY basket trial
  • Additional interim data to be presented from Cohorts 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgAN
  • Research presentations include the preclinical efficacy profile of CHK-336 and multiple abstracts detailing Chinook's multidimensional approach to precision medicine in nephrology
  • Chinook to host investor conference call and webcast on November 4, 2022 to review and discuss the abstracts and provide corporate updates

SEATTLE, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced nine abstracts to be presented at ASN Kidney Week 2022 from November 3 – 6, 2022 in Orlando, Florida. Five abstracts will be presented as posters, one abstract will be delivered as an oral presentation and three abstracts will be presented as informational posters.

Chinook will host a live conference call and webcast on Friday, November 4, 2022 at 6:30 pm EDT to review and discuss the abstracts and provide corporate updates. Members of the Chinook executive team will be joined by Sreedhar A. Mandayam, MD, MPH, MBA, FASN, Professor of Nephrology at the University of Texas MD Anderson Cancer Center and Baylor College of Medicine and Laura Kooienga, MD, practicing nephrologist and director of research at Colorado Kidney Care, for a discussion on Chinook’s programs.

Poster Presentations

TH-PO497: 
  Atrasentan for the Treatment of IgA Nephropathy: Interim Results from the AFFINITY Study
Presenting Author:   Anjay Rastogi, M.D., Ph.D., University of California, Los Angeles
Session Title:   Glomerular Diseases: Clinical, Outcomes, Trials - I
Session Time:   Thursday, November 3rd ​at 10:00 am – 12:00 pm​ EDT


FR-PO659:    Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients with IgA Nephropathy
Presenting Author:   Jonathan Barratt, Ph.D., F.R.C.P., University of Leicester & Leicester General Hospital, Leicester, UK
Session Title:   Glomerular Diseases: Clinical, Outcomes, Trials - II
Session Time:   Friday, November 4th at ​10:00 am – 12:00 pm EDT


TH-PO419:   Single Nuclei RNA-seq Reveals Cell-type Specific Responses to Disease and Enalapril in the gddY Mouse Model of IgAN
Presenting Author:   Eric Olson, Ph.D., Chinook Therapeutics
Session Title:   Glomerular Diseases: Inflammation and Fibrosis
Session Time:   Thursday, November 3rd at ​10:00 am – 12:00 pm EDT


FR-PO334:   Preclinical Efficacy of CHK-336: A First in Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Primary Hyperoxalurias
Presenting Author:   Jennifer Cox, Ph.D., Chinook ​Therapeutics
Session Title:   Genetic Diseases: Models, Mechanisms, Treatments
Session Time:   Friday, November 4th ​at 10:00 am12:00 pm EDT

       

SA-PO1011:   Unsupervised Characterization of the NURTuRE Cohort Reveals Gene Expression and Tissue Remodeling Dynamics along a Synthetic CKD Progression Axis
Presenting Author:   Tobias Bohnenpoll, Ph.D., Evotec SE
Session Title:   CKD Pathobiology - II
Session Time:   Saturday, November 5th at ​10:00 am – 12:00 pm EDT


Oral Presentation

FR-OR60:    A Multi-Omics Approach to IgA Nephropathy Characterization in the NURTuRE Cohort Enables Precision-Based Treatment Approaches
Presenting Author:   Eric Olson, Ph.D., Chinook Therapeutics
Session Title:   Glomerular Diseases: From Bench to Bedside
Session Time:   Friday, November 4th at ​4:30 – 6:00 pm EDT


Informational Posters

INFO27:    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy – The ALIGN Study
Presenting Author:   Hiddo Heerspink, Ph.D., University Medical Center Groningen, the Netherlands
Session Time:   Thursday, November 3rdSaturday, November 5th at 10:00 am12:00 pm EDT

               

INFO31:   Atrasentan in Patients with Proteinuric Glomerular Diseases – The AFFINITY Study
Presenting Author:   Michelle Rheault, M.D., University of Minnesota
Session Time:   Thursday, November 3rdSaturday, November 5th at​ 10:00 am12:00 pm EDT

                

INFO28:   A Phase 1/2 Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IgA Nephropathy
Presenting Author:   Jonathan Barratt, Ph.D., F.R.C.P., University of Leicester & Leicester General Hospital, Leicester, UK
Session Time:   Thursday, November 3rdSaturday, November 5th at​ 10:00 am12:00 pm EDT


For more information on these and other abstracts, please visit the ASN Kidney Week 2022 website.

Investor Conference Call Details
To access the call, please dial (800) 715-9871 (domestic) or (646) 307-1963 (international) and provide the Conference ID 7505851 to the operator.

To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcast will remain available for replay on Chinook’s website for 90 days.

About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 healthy volunteer trial. In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.


Contact:
Noopur Liffick
Vice President, Investor Relations & Corporate Communications
investors@chinooktx.com
media@chinooktx.com

Primary Logo

Source: Chinook Therapeutics, Inc.

IR Contact

Noopur Liffick

Vice President
Investor Relations & Corporate Communications
investors@chinooktx.com